By Jorge Aura
All investors know the risks of biotechnology companies. The strong volatility of these companies makes their prices fluctuate in excess. This sector has the peculiarity that offers a high risk but with a possible high gain. Identify pharmaceutical companies that have bottomed out or that are undervalued can be a good investment strategy for medium-term and short-term. In the following table will be able to see the readers, 3 companies which have greatly reduced their quoted prices since on January 6, 2017.
| Company | January 6, 2017 | July 7, 2017 | |
| Galena Biopharma Inc | $2.07 | $0.55 | |
| Repros Therapeutics Inc | $1.36 | $0.50 | |
| Navidea Biopharmaceuticals Inc | $0.625 | $0.49 |
As you have seen in the upper table these companies have been hit hard during July, 2017. To determine if these companies are undervalued I have made a fundamental analysis of each company.
Galena Biopharma Inc (NASDAQ: GALE) is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets.
Source: Google finance
Galena lead product candidate is GALE-401. This product contains the active ingredient anagrelide, an FDA-approved product, for the treatment of patients with myeloproliferative neoplasms ("MPNs") to lower abnormally elevated platelet levels. The currently available immediate release ("IR") version of anagrelide causes adverse events that are believed to be dose and plasma concentration dependent, and may limit the use of the IR version of the drug. Therefore, reducing the maximum concentration ("Cmax") and increasing the half-life of the drug is hypothesized to reduce the side effects, while preserving the efficacy, potentially allowing a broader use of the drug.
Source: Galena Biopharma Inc
Galena Biopharma has a market cap of $21.18 million. Its trailing P/E is 2.51. It has a total cash position on its balance sheet of just $42.046,Million. The company announced a revenue on three months ended March 31 of $0.
Source: Stockcharts.com
This stock plunged from its high of $4.75 to a recent low of $0.16. If you are bullish on this stock, I would look to be a buyer on the next high-volume move above some near-term overhead resistance at $0.58 a share. Look for volume that's tracking in close to or above its three-month average action of 599,062 shares. Keep in mind that the company has approved the possibility of performing a reverse split recently.
Repros Therapeutics Inc (NASDAQ: RPRX) is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.
Source: Google finance
Repros Therapeutics has a market cap of $16.98 million. Its trailing P/E is incalculable and its forward P/E is just incalculable as the majority of pharmaceutical companies of small-capitalization. It has a total cash position on its balance sheet of just $3.23 Million. The company announced a revenue on three months ended March 31 of $0.
This stock plunged from its high of $2.48 to a recent low of $0.33. If you are bullish on this stock, I would look to be a buyer on the next high-volume move above some near-term overhead resistance at $0.58 a share. Look for volume that's tracking in close to or above its three-month average action of 905,240 shares.
Navidea Biopharmaceuticals Inc (NYSEAMEX: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease.
Source: Google finance
Navidea has a market cap of $78.10 Million. Its trailing P/E is incalculable and its forward P/E is just incalculable as the majority of pharmaceutical companies of small-capitalization. It has a total cash position on its balance sheet of just $13.44 Million. The company announced a revenue on three months ended March 31 of $580,000.
This stock plunged from its high of $1.16 to a recent low of $0.26. If you are bullish on this stock, I would look to be a buyer on the next high-volume move above some near-term overhead resistance at $0.50 a share. Look for volume that's tracking in close to or above its three-month average action of 386,176 shares.
Disclosure: Jorge Aura has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. Jorge Aura wrote this article himself, and it expresses his own opinions. He is not receiving compensation for it. Jorge Aura has no business relationship with any company whose stock is mentioned in this article.
7 comentarios:
The post is truly great, I appreciate your intention to explain all issues you've encountered with! Knowing the risks of biotechnology companies, we can simply set up particular strategies to avoid different issues.
This is an excellent article. For me, this is a fascinating topic. This website offers numerous advantages. This website gave me a lot of useful information. It helps me in a number of ways. Thank you very much for making this information available.
When faced with a difficult case study solver, many students turn to the internet for help. There are a number of online resources that offer case study solutions, but not all of them are reliable. It is important to carefully research any site before using its services.
Many students don't know where to go for finance assignment helper. We provide finance assignment help with expert writers who are qualified to write on any finance topic.
Engaging in investments with undervalued pharmaceutical companies can present a challenging yet potentially lucrative approach, as evidenced by the table showcasing three enterprises that have encountered substantial decreases in their stock prices.Iam a professional academic content writer and I also offer an online
Professional Essay Writers to the students at a cheap rate.
Exploring biopharma stocks is like uncovering hidden treasures among small caps. These undervalued gems hold the potential for significant growth, much like navigating the diverse offerings in a tiger exchange.
These small-cap stocks, despite being undervalued, have significant potential for growth and profitability. Investing in biopharma stocks offers the chance to support innovative medical advancements while potentially yielding substantial returns on investment.
Post a Comment